Zelluna Immunotherapy appoints Jens-Peter Marschner as chief medical officer
Oslo, Norway, June 25, 2019 - Zelluna Immunotherapy, the biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need, announces the appointment of Jens-Peter Marschner as chief medical officer (CMO).
“Zelluna is now primarily focused on taking its lead TCR in the clinic to demonstrate therapeutic potential. As a result, it is critical to appoint an experienced CMO at this time to lead the clinical development of our cell therapies,” said Miguel Forte, CEO, Zelluna. “We selected Jens-Peter based on his extensive knowledge and experience in therapeutic development within oncology. He will make an immediate impact in our aim to drive Zelluna TCRs into the clinic. Completing Zelluna’s highly experienced and collectively focused senior management team is a major milestone to achieving these goals.”
Jens-Peter Marschner is a medical doctor bringing to Zelluna more than 20 years experience in clinical development and medical affairs with a focus on biological compounds in oncology and immuno-oncology development. Prior to joining Zelluna, Jens-Peter was the Medical Lead Oncology for Western Europe and Canada at Abbvie. Previously, as CMO for Affimed, he was responsible for clinical strategy and development of its bi-specific antibodies. He significantly supported Affimed’s transition from a technical platform company to a clinical development company. He has also been a clinical team leader for Merck KGaA, contributing significantly to the successful launch of cetuximab, and was VP in different medical and clinical leadership positions including immuno-oncology. Jens-Peter has also held senior roles at Bayer and Boehringer Mannheim.
“Zelluna’s unique TCR-T approach has the potential to revolutionize treatments of solid tumors and provides hope for oncology patients,” said Jens-Peter Marschner, CMO, Zelluna. “It is a pleasure to be part of this passionate management team and I am happy that I can contribute to a successful development of a new generation of oncology therapies.”
About Zelluna Immunotherapy
Zelluna Immunotherapy specializes in immunotherapies targeting a broad range of solid cancers with a high unmet medical need. The company is developing a unique portfolio of non-engineered tumor specific T-cell receptors (TCRs) isolated from long-term surviving patients from cancer vaccine trials. The TCRs combine specificity and affinity to have the potential for a safe and efficient therapy to target a variety of common cancer types. Zelluna, in addition to internal competences, has a long-term agreement with the Department for Cell Therapy at Oslo University Hospital, providing comprehensive capabilities of TCR development, ranging from lead discovery to clinical translation. For more information, please visit www.zelluna.com.